Bevacizumab biosimilar - Cipla BioTec

Drug Profile

Bevacizumab biosimilar - Cipla BioTec

Alternative Names: CBT-124

Latest Information Update: 30 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cipla BioTec
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 22 Aug 2016 Cipla BioTec plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Inoperable or Unresectable, Recurrent, Metastatic disease, First-line therapy, Combination therapy) Bulgaria, India, Hungary, South Africa and Ukraine (IV) (NCT02879097)
  • 01 Jun 2016 Phase-I clinical trials in Cancer (In volunteers) in New Zealand (IV)
  • 29 Apr 2016 Preclinical trials in Cancer in Australia (IV) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top